Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.
[1] It was founded in 2008 by Osman Kibar.
[2] Samumed's products in development target novel components of the Wnt signaling pathway.
[3][4][5] The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced.
This United States corporation or company article is a stub.